[en] Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this study was to evaluate the efficacy and safety of this new long-acting formulation in a large population of acromegalic patients previously responsive to lanreotide 30 mg, im (sustained release microparticle formulation). Lanreotide Autogel was administered by deep sc injection every 28 d to 107 patients (54 males and 53 females; mean age, 54 +/- 1.2 yr). All patients had been treated with lanreotide (30 mg) for at least 3 months before study entry and had a mean GH level less than 10 ng/ml after at least 4 subsequent im injections every 14 d (48%), 10 d (32%), or 7 d (20%). Treatment was switched from lanreotide 30 mg injected every 14, 10, or 7 d to 60, 90, or 120 mg lanreotide Autogel, respectively, every 28 d. After three fixed dose injections of lanreotide Autogel, mean lanreotide levels were similar to those obtained at steady state with lanreotide 30 mg. During lanreotide Autogel treatment, the control of acromegalic symptoms was comparable with that previously achieved during lanreotide 30 mg treatment. After 3 injections of lanreotide Autogel, mean GH (2.87 +/- 0.22 ng/ml) and IGF-I (317 +/- 15 ng/ml) values were comparable with those recorded at the end of lanreotide 30 mg treatment (GH, 2.82 +/- 0.19 ng/ml; IGF-I, 323 +/- 16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized IGF-I were achieved in 33% and 39% of patients during lanreotide 30 mg and lanreotide Autogel treatment, respectively. Diarrhea, abdominal pain, and nausea were reported by 38%, 22%, and 18% of patients during lanreotide 30 mg treatment and by 29%, 17%, and 9% of patients, respectively, during lanreotide Autogel treatment. In conclusion, this clinical study shows that lanreotide Autogel is at least as efficacious and well tolerated as lanreotide 30 mg. This new long-acting lanreotide formulation, lanreotide Autogel, which is administered from a small volume, prefilled syringe by deep sc injection, is therefore likely to improve the acceptability of medical treatment for patients requiring long-term somatostatin analog therapy.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Caron, Ph
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Cullen, C. R.
Goth, M. I.
Gutt, B.
Laurberg, P.
Pico, A. M.
Valimaki, M.
Zgliczynski, W.
Language :
English
Title :
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
Publication date :
January 2002
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Society, Chevy Chase, United States - Maryland
Harris A.G., Prestele H., Herold K., Boerlin V. (1987) Long term efficacy of sandostatin (SMS 201-995, octreotide) in 178 acromegalic patients. Results from the international multicentre acromegaly study group. Sandostatin in the treatment of acromegaly , Lamberts SWJ, ed. Consensus round table, Amsterdam. Berlin: Springer; 117-125.
Lamberts S.W., Uitterlinden P., Del Pozo E. (1987) SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab 65:703-710.
Sassolas G., Harris A.G., James-Deidier A. (1990) Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab 71:391-397.
Morange I., De Boisvilliers F., Chanson P., Lucas B., DeWailly D., Catus F., Thomas F., Jaquet P. (1994) Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 79:145-151.
Giusti M., Gussoni G., Cuttica C.M., Giordano G. (1996) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study. J Clin Endocrinol Metab , Italian Multicenter Slow Release Lanreotide Study Group; 81:2089-2097.
Caron P., Cogne M., Gusthiot-Joudet B., Wakim S., Catus F., Bayard F. (1995) Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 132:320-325.
Caron P., Morange-Ramos I., Cogne M., Jaquet P. (1997) Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82:18-22.
Baldelli R., Colao A., Razzore P., Jaffrain-Rea M.L., Marzullo P., Ciccarelli E., Ferretti E., Ferone D., Gaia D., Camanni F., Lombardi G., Tamburrano G. (2000) Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 85:4099-4103.
Lamberts S.W.J., Van der Lely A.J., De Herder W.W., Hofland L.J. (1996) Octreotide. N Engl J Med 334:246-254.
Ikuyama S., Nawata H., Karo K., Ibayashi H., Nakagaki H. (1986) Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. J Clin Endocrinol Metab 62:729-733.
Reubi J.C., Landolt A.M. (1989) The growth hormone responses to octreotide in acromegaly correlate with adenoma sandostatin receptors. J Clin Endocrinol Metab 68:844-850.
Spada A., Arosio M., Bochicchio D., Bazzoni N., Vallar L., Bassetti M., Faglia G. (1990) Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cylase. J Clin Endocrinol Metab 71:1421-1426.
Kuhn J.M., Basin C., Beaudoin C., Emy P., Mollard M., De Rouge B., Schatz B. (1992) Influence de la dose et des modalités d'administration du BIM 23014 sur la sécrétion d'hormone de croissance de l'acromégale. Ann Endocrinol 53:208-214.
Barnard L.B., Grantham W.G., Lamberton P., OíDorisio T.M., Jackson I.M. (1986) Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). Ann Intern Med 105:856-861.
Stewart P.M., Kane K.F., Stewart S.E., Lancranjan I., Sheppard M.C. (1995) Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 80:3267-3272.
Flogstad A.K., Halse J., Bakke S., Lancranjan I., Marbach P., Bruns C., Jervell J. (1997) Sandostatin LAR in acromegalic patients: Long-term treatment. J Clin Endocrinol Metab 82:23-28.
Lancranjan I., Atkinson A.B. (1999) Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Pituitary 1:105-114.
Newman C.B., Melmed S., Snyder P.J., Newman C.B., Melmed S., Snyder P.J., Young W.F., Boyajy L.D., Levy R., Stewart W.N., Klibanski A., Molitch M.E., Gagel R.F. (1995) Safety and efficacy of long term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab 80:2768-2775.
Giustina A., Barkan A., Casanueva F.F., Cavgnini F., Frohman L., Ho K., Veldhuis J., Wass J. (2000) Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 85:526-529.
Caron P., Tabarin A., Cogne M., Chanson P., Jaquet P. (2000) Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: Clinical implications. Eur J Endocrinol 142:565-571.
Vance M.L., Harris A.G. (1991) Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch Internal Med 151:1573-1578.
Heron I., Thomas F., Dero M., Gancel A., Ruiz J.M., Schatz B., Kuhn J.M. (1993) Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 76:721-727.